Apixaban Dose Reduction in Patients With Elevated Drug Levels

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT02809469

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02809469
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02809469. Allocation not applicable; no masking; primary purpose prevention. Start 2016-08 (registry gives no type); primary completion 2018-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Apixaban Dose Reduction in Patients With Elevated Drug Levels
Acronym
ADREL
Intervention (Drug)
apixaban dose reduction
Lead sponsor
Hamilton Health Sciences Corporation (class: other)
Collaborator
Population Health Research Institute (class: other)

Record details

Record id
cardio:ct-nct02809469
Content hash
adf583f6ebe8a51cff64a895b8ccd360396ccd89f08347b4897d4fce7146a754